On the other hand, delivery of VEGF-A to the brains of mouse AD models partially rescued vascular loss, reduced amyloid plaque load, and rescued impaired memory (Religa et al., 2013; Garcia et al., 2014) as did intraperitoneal VEGF administration (Wang et al., 2011). The gene discussed is VEGFA; the disease is amyloidosis.